Objective: Red blood cell (RBC) transfusions can suppress erythropoiesis. On this basis, RBC transfusions administered to very low birth weight (VLBW) neonates potentially render them more likely to qualify for a subsequent transfusion.
Introduction
Erythrocyte transfusions can provide important benefits; indeed they can be life-saving, but they also carry risks. [1] [2] [3] [4] Advances in transfusion medicine have significantly reduced many of these risks, such as transfusion-acquired infections. 5, 6 Despite these advances, certain transfusion problems remain. Among these is the suppressive effect of red blood cell (RBC) transfusions on erythropoietin production and thereby on erythropoiesis. [7] [8] [9] In the developing fetus and neonate, endogenous erythropoietin has important neuroprotective and neurodevelopmental properties. [10] [11] [12] Repeatedly suppressing erythropoietin production by repeated erythrocyte transfusions might have unwanted neurodevelopment effects in this population. Moreover, suppressing erythropoiesis by transfusions might render a very low birth weight (VLBW) neonate more likely to qualify for and receive additional transfusions.
Darbepoetin (Aranesp, Amgen, Thousand Oaks, CA, USA) is a long-acting form of recombinant erythropoietin, with the advantages that it can generally be given less frequently and at lower cost. 13, 14 On the basis of our pharmacokinetic studies of darbepoetin administration to VLBW neonates, [15] [16] [17] we hypothesized that when a neonate qualifies for a late RBC transfusion, a single dose of darbepoetin would counteract the transfusion's erythrosuppressive effect. The single-dose concept was derived from our studies, [15] [16] [17] and that of Freise et al., 18 who calculated that among VLBW neonates, only a modest increase in plasma erythropoietin is needed to effectuate a several-fold increase in erythropoiesis. With this information, we reasoned that the strategy of single-dose darbepoetin administration accompanying a late transfusion might be worth testing as a means of preventing further NICU transfusions. We devised this pilot trial to provide preliminary data for assessing this theory and to provide information with which a future transfusion-avoidance trial might be constructed.
Methods
This was a single-centered randomized trial involving VLBW neonates who qualified for a late RBC transfusion according to the Intermountain Healthcare NICU transfusion guidelines. 19 The transfusion guidelines were initiated in 2002 and revised in 2004. In brief, the guidelines recommend RBC transfusion if the hematocrit falls below 35% for a patient on mechanical ventilation, below 27% for a neonate on supplemental oxygen or with signs of anemia but not on mechanical ventilation, and below 20% for any NICU patient. In a previous study we reported that in the McKay-Dee NICU, 70% of RBC transfusions were compliant with these guidelines. 19 The RBCs transfused (15 ml per kg body weight) were supplied by the American Red Cross Blood Center, Salt Lake City, UT, USA, and were irradiated, leukoreduced, stored in CPDA-1, not washed before transfusion, and administered over a period of 3½ to 4 h.
For this study, 20 VLBW infants were selected to form a convenience sample, on the basis that this number would likely inform us whether a single dose of darbepoetin given concomitantly with the transfusion would result in any difference in reticulocyte count or hemoglobin/hematocrit. For randomization, a computer-generated set of random numbers was produced by the research pharmacy department. The pharmacist was the only individual with access.
The darbepoetin was given subcutaneously by a research nurse at a dose of 10 mg per kg body weight. Dosing was within 30 min of initiating the transfusion.
Serum lactate concentrations were measured using the ABL800 FLEXQ (Radiometer, Brnshj, Denmark) and were run immediately (within minutes) after drawing. The absolute reticulocyte count (ARC), reticulocyte percentage, hemoglobin and hematocrit were quantified using a LH-750 hematology analyzer (Beckman-Coulter, Hialeah, FL, USA). Values were drawn before the study transfusion and also at the following intervals after transfusion: 4 to 6 h, 18 to 24 h, 60 to 82 h and 7 to 10 days. The study was approved by the McKay-Dee Hospital Institutional Review Board and parents of the study subjects signed an approved informed consent document.
The program used for clinical data collection was a modified subsystem of Clinical Workstation. The 3M Company (Minneapolis, MN, USA) approved the structure and definitions of all data points for use within the program. Data were managed and accessed by authorized data analysts only. Statistics were calculated using Statit (Corvallis, OR, USA). Means and standard deviations or standard errors of the mean were used to express values in groups that were normally distributed. Differences in categorical variables were assessed using the Fisher exact test, and a Student t-test or a paired t-test was used to assess differences. Two-tailed testing was used. A mixed-model analysis of variance was used to compare repeated measures of reticulocyte count and hematocrits. Statistical significance was set as P<0.05.
Results
Parents of 22 VLBW neonates >14 days old who qualified for a RBC transfusion on the basis of our transfusion guidelines were provided with written study information and were engaged in a discussion about the study protocol. Two sets of parents declined participation and the other 20 consented. The 20 patients were randomly assigned to receive or not to receive (controls) a single dose of darbepoetin along with the transfusion. The two groups of 10 did not differ significantly from each other in the demographical features analyzed ( Table 1) . Two of the controls and two of the darbepoetin recipients were on mechanical ventilation at study entry. The remaining eight controls and six of the eight remaining darbepoetin recipients were on supplemental oxygen by nasal carnula at the time of study entry (the other two were on room air).
The 20 VLBW infants were generally 5 to 6 weeks old when they entered this study (Table 2 ). Most infants (60%) in both groups had received one or more previous RBC transfusions. The most proximate transfusion had generally been 2 to 4 weeks before they qualified for the present transfusion ( Table 2 ). None of the study participants were known to have a variety of anemia other than the anemia of prematurity.
All the 10 participants that were randomized to receive darbepoetin all did so and the 10 that were randomized to not receive darbepoetin did not. One protocol violation was discovered; namely, one control infant (no darbepoetin) was given a repeat RBC transfusion on the third day of study. This transfusion was not compliant with the transfusion guidelines and no explanation for the transfusion order was recorded. However, the data from this patient were included in the analysis.
Blood lactate concentrations in the 10 darbepoetin recipients were 1.7 ± 0.4 mm l À1 before the transfusion and 1.3 ± 0.4 mm l À1 after (P ¼ 0.03), with no further change recorded during the study. Lactate concentrations in the 10 controls were 1.8±0.7 mm l À1 before the transfusion and 1.5 ± 0.9 mm l À1 after (P ¼ 0.44), with no change recorded during the study. Reticulocyte counts changed with effects due to time, treatment and a time by treatment interaction. Post-hoc tests comparing baseline values with post-transfusion values found that reticulocytes were significantly elevated for the darbepoetin recipients and significantly decreased for the controls. The time courses of these changes are illustrated in Figure 1 .
The time courses of hematocrit changes are illustrated in Figure 2 . In the darbepoetin recipients and the controls, hematocrit increased rapidly after transfusion and remained elevated through the 7-to 10-day study period. Post-hoc tests indicated that the hematocrits were similar in the darbepoetin recipients vs the controls (P ¼ 0.089). At the end of the experiment, darbepoetin recipients had hematocrits 12.4 ± 2.8 points higher than their pretransfusion values and controls had hematocrits 8.1±4.9 points higher than their pre-transfusion hematocrits (P ¼ 0.033).
By design, the study blood tests (lactate, reticulocyte count, hemoglobin and hematocrits) ceased after 7-to 10-day values were obtained. Therefore, the diverging reticulocyte counts and hematocrits of the control vs darbepoetin groups were not followed beyond that point. Only one of the 20 study subjects qualified for and received a subsequent RBC transfusion during the hospitalization.
Discussion
RBC transfusions administered to VLBW neonates are sometimes categorized as 'early' or 'late'. 20 Early transfusions, those given during the first week or so after birth, are generally ordered because of a decreasing hemoglobin concentration due to phlebotomy losses for laboratory tests. 20 In contrast, late transfusions, those given after the first or second week, are generally ordered because of a falling hemoglobin associated with the normocytic, normochromic, hyporegenerative anemia termed the anemia of prematurity. 21, 22 Early and late RBC transfusions might each provide certain benefits to VLBW neonates, but both carry risks. Because of known and unknown risks, any successful efforts to eliminate unneeded transfusions could improve patient outcomes, conserve valuable blood-bank resources and reduce intensive care costs.
Risks of late RBC transfusions include transfusion-associated infection, 23, 24 TRALI reactions, 25 their association with a subgroup Table 2 PRBC transfusions administered to 20 VLBW neonates before they were entered into the study
Day of life when the study transfusion was given 44 ± 18 31 ± 12 0.73 Percent that had received one or more transfusions before study entry 60 60 1.00 Number of transfusions received before study entry 3.0 ± 4.4 2.1 ± 3.9 0.65 Days before study entry when the previous transfusion was given 30±14 22±13 0.33
Abbreviations: n, number of study subjects; PRBC, packed red blood cell; VLBW, very low birth weight. The values shown are mean ± s.d. or percent. of necrotizing enterocolitis 26 and transfusion-associated graft versus host disease. 27 Another unwanted effect of late transfusions in this population is their suppressive effect on erythropoietin production and therefore on erythropoiesis. [7] [8] [9] The consequences of repeatedly suppressing erythropoietin production in a developing pre-term neonate are not known. In this study we saw evidence of transfusion-induced erythropoietic suppression in the form of falling reticulocyte counts following transfusion. In contrast, a single dose of darbepoetin given at the time of transfusion produced an opposite effect, with a significant increase in reticulocyte count.
Change in Absolute Reticulocyte
We recognize that a higher reticulocyte count and a slightly higher hematocrit may not be clinically meaningful outcomes in a study such as this. A more important outcome, but one for which this study was not designed nor powered, would be whether the single darbepoetin dose prevented additional transfusions. From our pilot experience, we suggest that a study with such an aim should enroll neonates sooner than we did. Specifically, we studied VLBW neonates who were generally 5-to 6-weeks old, corresponding closely with the expected time of their anemia of prematurity nadir, as shown by Wardrop et al. 28 The fact that 19 of the 20 received no further RBC transfusions is in keeping with the observations by Wardrop et al. 28 and Stockman et al. 29 that once the nadir is passed, further transfusions are seldom needed. Thus, in a future transfusion avoidance study, it would be much better to enroll VLBW neonates qualifying for a transfusion during their second or third week, because avoidance of additional transfusions among these would be more likely.
We suspect, with this exception, whether the basic design of this study could be carried forward to a transfusion-avoidance trial. These design aspects include the dose of darbepoetin we used, the subcutaneous route and the fact that only a single dose was given. Following the reticulocyte count and hematocrit weekly through the remainder of the NICU stay would be a useful addition to the present design. Such information could clarify the length of effect of the single dose of darbepoetin, and could also clarify the time required for recovery from the transfusion-induced erythropoietic suppression.
We recognize that our use of convenience sampling in the current design prevents generalizing the results to a larger population; hence, additional study is required. Moreover, we emphasize that a larger study, and one focused on the outcome of transfusion avoidance, is necessary before it can be determined whether the concept of single-dose darbepoetin administration accompanying RBC transfusion should be incorporated into clinical practice.
